Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity-Reference-Cited by-同舟云学术

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

Published:2017-01-09 Issue:2 Volume:23 Page:242-249
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ghosh Arnab,Smith Melody,James Scott E,Davila Marco L,Velardi Enrico,Argyropoulos Kimon V,Gunset Gertrude,Perna Fabiana,Kreines Fabiana M,Levy Emily R,Lieberman Sophie,Jay Hillary V,Tuckett Andrea Z,Zakrzewski Johannes L,Tan Lisa,Young Lauren F,Takvorian Kate,Dudakov Jarrod A^ORCID,Jenq Robert R,Hanash Alan M,Motta Ana Carolina F^ORCID,Murphy George F,Liu Chen,Schietinger Andrea,Sadelain Michel,van den Brink Marcel R M

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4258.pdf

Reference43 articles.

1. Ho, W.Y., Blattman, J.N., Dossett, M.L., Yee, C. & Greenberg, P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3, 431–437 (2003).

2. Sadelain, M., Rivière, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003).

3. Gill, S. & June, C.H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263, 68–89 (2015).

4. Sadelain, M., Brentjens, R. & Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388–398 (2013).

5. James, S.E. et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 114, 5454–5463 (2009).

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

2. Chimäre Antigenrezeptor-T-Zellen – Die Evolution zellulärer Immuntherapie von malignen zu nicht-malignen Erkrankungen;Aktuelle Rheumatologie;2024-08

3. Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors;Cell Death & Disease;2024-05-24

4. Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation;Cytotherapy;2024-05

5. Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation;Leukemia;2024-04-17